Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites

Journal Article · · J. Med. Chem.; (United States)
DOI:https://doi.org/10.1021/jm00127a014· OSTI ID:5604231
We have radiolabeled a structural analogue of indolidan, a potent phosphodiesterase-inhibitor cardiotonic, to permit biochemical studies regarding the interaction of this class of drugs with their pharmacological receptor. (/sup 3/H)-LY186126 (1,3-dihydro-3,3-dimethyl-1-(/sup 3/H3)methyl-5-(1,4,5,6-tetrahydro-4-me thyl-6- oxo-3-pyridazinyl)-2H-indol-2-one; (/sup 3/H)-3) was selected as a synthetic target because of its potency as a cardiotonic and the ability to readily incorporate three tritia via the indolone N-CH3 substituent. Alkylation of a desmethyl precursor with tritium-labeled iodomethane resulted in (/sup 3/H)-3 with a radiochemical purity of 98% and a specific activity of 79.2 Ci/mmol. This radioligand binds with high affinity to myocardial membrane vesicles. The binding was saturable, and Kd and Bmax values of 4.1 nM and 383 fmol/mg protein were obtained. A series of indolidan congeners displaced (/sup 3/H)-3 bound to myocardial vesicles, and Ki values for inhibition of binding were highly correlated with canine inotropic ED50 values, suggesting the specific binding of (/sup 3/H)-3 to cardiac vesicles is pharmacologically relevant.
Research Organization:
Lilly Corporate Center, Indianapolis, IN (USA)
OSTI ID:
5604231
Journal Information:
J. Med. Chem.; (United States), Journal Name: J. Med. Chem.; (United States) Vol. 32:7; ISSN JMCMA
Country of Publication:
United States
Language:
English